Develop a new drug for someone Who might be suffering somewhere in the world.



    Let's open up new markets and revenue streams by predicting more than one promising indication for a drug candidate at the early development stage. We are a specialized discovery team with novel technologies and unique massive bio-pharmacological data resources for discovering hidden possibilities of drugs.


    Two major causes of failure in clinical trials are lack of safety (~45% failure rate in Phase I) and efficacy (~65% failure rate in Phase II). A synergistic drug combination increases the efficacy of the therapeutic effect and reduces toxicity as a result of decreased dosage. Using our unique Multi-Strategy Drug Repositioning System, we will find the most synergistic drug partner that will target multiple pathological networks with your drug.


    In the process of researching for orphan diseases, one may come across the problem of a lack of information. That's where we step in. We can predict the pathological networks and suggest suitable drugs for diseases, on which you may have limited knowledge.


Our Special Technology


Recent news & Event

DR. NOAH BIOTECH CEO JI-HYUN LEE Giving Presentation at ‘THE AI KOREA 2020 Conference\'

DR. NOAH BIOTECH CEO JI-HYUN LEE gave a presentation titled Designing Drug Combinations for Orphan Diseases at ‘THE AI KOREA 2020 Conference’ held online on 27th.In its introductory remark, Ms. Lee said, "Our effort to incorporate AI technology into pharmaceutical development to increase efficiency and shorten the development period has continued up to now. In the global market, biotech companies, equipped with AI technology, are rubbing shoulders with multinational pharmaceuticals to develop new drugs with great success by attracting investment worth tens of and hundreds of billions of won. The country already saw more than ten AI companies jumping into the competition to bring a new drug ...


Dr. Noah Biotech, 4.5 billion KRW Series A “2 types of new drugs to undergo clinical trials next year”

Biospectator Journalist  Jongwon JangBNH Investment, KB Investment, POSCO Capital, and T Investment as participants… R&D starting with stroke and amyotrophic lateral sclerosis medicine as well as DMD and SMADr. Noah Biotech has succeeded in attracting investments of 4.5 billion KRW for Series A. With these investments, Dr. Noah Biotech will complete preclinical studies on its leading products, stroke and amyotrophic lateral sclerosis (Lou Gehrig's disease) medicine, and will launch its first clinical trials next year. According to Dr. Noah Biotech on the 12th, KB Investment, POSCO Capital, and T Investment participated in the investment by taking over common shares under the lead of BN ...


AI technology-based system applied in rare disease treatment leads to the development of new treatments (Monthly People May 2020)

AI technology-based system applied in rare disease treatment leads to the development of new treatments Under a ‘pilot project to build bio-big data for all ministries,’ promoted by three ministries including the Ministry of Science and ICT, big data on genomic information, such as rare diseases, of 20,000 people is being established. With this, there is a growing interest in developing medicines for rare diseases. Dr. Noa Biotech, a drug development company that uses AI technology, continues to develop new drugs with focus on rare disease treatment through its own platform. ◆  Development of Rare Disease Treatment Using an Independent Platform DR stands for doctor, as well as " ...


Dr.NOAH publishes an article on AI-based target screening system in SCI-level international journal

A research paper titled "Structure- and Similarity-Based Prediction of Protein Targets for Drug-like Compounds," co-authored by a research team led by Professor Seok Cha-ok of Seoul National University and Dr. Noah Biotech, has been published in the SCI-level International Journal of Chemical Information and Modeling. This paper introduces the technology that, when there is a new drug structure, can quickly screen the proteins that the drug is likely to combine, among the numerous proteins, and effectively predict the target protein. Two approaches are mainly used to predict the bonds between proteins and compounds, each with its own limitations. Ligand-based method relying on similarity ...


Dr.NOAH selected as an a small and medium-sized venture enterprise for innovative growth support project in the field of BIG 3.

Dr. Noah Biotech is a company dedicated to developing rare disease combinations using the AI system. It was selected as an SME venture enterprise for innovation growth support project. This project identifies promising start-ups and venture companies in the field of BIG 3 and grants up to 1.2 billion won for the commercialization or R&D funding, or up to 13 billion won per selected company for the policy funding or technology financing. Dr. Noah Biotech is focusing on developing its own treatment for neurological and muscular diseases by utilizing artificial intelligence technology in the world's first compound design system. It prioritizes the technology transfer of the newly discovered ...


Kainos Medicine signs a joint research agreement with AI new drug development company Dr. Noah Biotech

Predicting new drug structures through the AI platformExpected to build a new pipeline[Financial News] Kainos Medicine, a company pursuing a merger listing with Hana Financial 11th Special Purpose Acquisition Company, announced on the 25th that it will be developing new drugs using artificial intelligence (AI) technology.Kainos Medicine signed a joint research agreement with Dr. Noah Biotech, which is an AI-based new drug development specialist.In this joint agreement, Dr. Noah Biotech will provide the structure of substances optimized for the target disease. Based on this, Kainos Medicine plans to derive new drug candidates through matter synthesis and optimization.Kainos Medicine is c ...


Huons-DR.NOAHbiotech Co., Ltd. to Collaborate on New Drug Development Based on AI

The main purpose of the agreement is to build a new next-generation drug pipeline through mutual cooperation and joint research based on the AI system owned by DR.Noahbiotech, and ultimately develop a new innovative AI drug. Huons has been making systematic preparations over the past year, maintaining continued business exchanges and cooperative ties with various AI companies at home and abroad for the development of new AI drugs that have come under the spotlight in the global bio industry. "The possibility and potential of new drug development and AI system held by DR. Noahbiotech are very good." said a representative for Huons. "We concluded an agreement by thinking that we can ...


DR.NOAH Biotech.Co.,Ltd. Establishment of research institute.

Direct verification of predictive compounds through "ARK" system.<  Laboratory entrance > <  Internal view > < Culture room >< Equipment room > ...




(16229) 경기도 수원시 영통구 창룡대로 256번길 91, 에이스광교타워2 1303호
(16229) ACE Gwanggyo Tower2 1303Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea